Jeff Liter

C-Suite Executive in the Life Sciences

Cell Therapy Experience

  • CEO of B-MoGEN Biotechnologies, leading the CAR T industry with novel non-viral gene delivery platform

  • Formerly COO of PCT - $20M cell therapy contract development and manufacturing organization 

Career Highlights

  • Currently CEO of two life science start-ups transforming the way cancer is treated

    • President and CEO B-MoGen Biotechnologies

      • Led $1.5M Series A financing; commercializing the company's unique and novel gene editing IP, and developing company into leader in regenerative medicine

    • President, CEO and CFO, OX2 Therapeutics

      • Led $2M Series A financing; bringing novel checkpoint inhibitor to treat glioblastoma

  • C-Suite Executive with proven track record at profitably growing emerging companies / business divisions

    • Completed turnaround of a cGMP services business to its first ever profitable state in 1st full year

    • Led from start to finish 10+ M&A transactions from $4M to $2.6B

    • Delivered an on-time and under budget NDA filing for new multiple myeloma drug

    • Raised capital for three distinct start up organizations enabling the start-up of their operations

    • International experience across three distinct industries with most recent being life sciences

Education

  • MBA: University of Minnesota

  • BS, Business Administration and Industrial Technology: Illinois State University

Connect With Us

Cell One Partners

200 Central Park South

Suite 12Q

New York City, NY 10019

E: info@cellonepartners.com

© 2019 Cell One Partners